Health Canada recall
This article was originally published in The Tan Sheet
Health Canada announces July 27 consumers should not use unauthorized smoking cessation product Resolve because of potential health risks. The product contains Cestemenol-350, which may result in damage to the kidney, liver or red blood cells, according to Health Canada. Resolve, distributed by The Winning Combination, is advertised as a natural stop-smoking aid comes in cool peppermint and wild cherry flavors. FDA says it is unaware of any marketing of the product in the U.S. except through onlinemarketing or from Canadian sources. Health Canada said it was is recalling the product immediately...
You may also be interested in...
The Winning Combination should discontinue claims that its Resolve smoking cessation aid is "clinically proven" to help smokers quit "once and for all" with "less stress and anxiety," the National Advertising Division says Oct. 28. NAD advises the advertiser to discontinue broad efficacy claims and some testimonials. The Winnipeg, Manitoba-based firm claims Resolve has natural ingredients and that the key ingredient ethyl maltol reduces cigarette consumption. The Winning Combination disagrees with NAD, but "will accede to the requests." GlaxoSmithKline, which sells Nicorette, Commit and NicoDerm CQ OTC NRT products, brought the challenge. In August 2008, Health Canada stated Resolve remains unauthorized for use there following a June 2007 advisory and recall the agency issued concerning the ingredient Cestemenol-350. The agency said in excessive amounts, Cestemenol-350 may cause damage to the kidney, liver or red blood cells (1"The Tan Sheet" Aug. 6, 2007, In Brief)
Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials.
US Ninth Circuit affirms a district court’s summary judgment in favor of Target and manufacturer of Up & Up brand biotin supplement it sells. Indian manufacturer targeted in putative class-action in New York prompted FDA’s 2016 creation of import alert category for Ayurvedic supplements.